What the Dexcom CONNECT Trial Proves About CGM in Type 2 Diabetes
Continuous glucose monitors for type 2 diabetes are wearable sensors that track glucose trends in real time, replacing many fingerstick checks and giving patients and clinicians continuous visibility into daily glucose patterns. The Dexcom CONNECT trial is the first major randomized controlled trial to show that a continuous glucose monitor can benefit adults with type 2 diabetes who are not using insulin, compared with usual care based on blood glucose meters. In this 26‑week study, participants on Dexcom G7 saw clinically and statistically significant reductions in HbA1c as well as better quality of glucose control, including more time in range and lower exposure to level 1 and 2 hyperglycemia. According to Roy Beck, MD, PhD, CONNECT delivers “the first and only level A evidence” for CGM in the non‑insulin type 2 population, a grading that often informs formal standards of care.
Why Level A Evidence Could Change CGM Access and Coverage
For people with type 2 diabetes not using insulin, CGM has often been viewed as optional, experimental or too expensive for insurers to cover widely. The Dexcom CONNECT trial changes that conversation by providing high‑grade clinical evidence in a real‑world primary care setting, across 22 practices and a broad mix of ages, genders, ethnicities, and income levels. CONNECT also showed extra HbA1c improvement when CGM was paired with common diabetes medications such as metformin, GLP‑1s and SGLT2s, strengthening the case that continuous monitoring complements existing drug therapy rather than replaces it. As payers and guideline committees weigh this level A evidence, the expectation from Dexcom leadership is that CGM could become a standard of care for CGM type 2 diabetes management beyond insulin users, potentially expanding reimbursement criteria and encouraging clinicians to recommend sensors earlier in the disease course.
Wearables Put CGM Data on the Wrist for Everyday Use
Clinical proof only matters if data reach people in a form they will use daily, which is where the modern glucose monitoring wearable comes in. Apple Watch, for example, can connect to compatible continuous glucose monitor systems so users can check their current reading, see whether glucose is rising or falling, view a short graph, and receive high or low alerts without pulling out their phone. Dexcom G7’s Direct to Apple Watch feature lets the sensor send readings via Bluetooth straight to the watch, offering a rare level of independence from the paired phone. These integrations extend CGM type 2 diabetes tools into everyday life, embedding glucose numbers alongside heart‑rate alerts, sleep summaries and reminders in Apple Health. For clinicians, Apple’s Health Sharing feature creates a path to bring selected glucose and lifestyle records into visits, helping explain recent patterns more clearly.
Tidepool’s Real‑World Data and Women’s Health Initiative Broaden the Evidence
While CONNECT offers randomized controlled trial evidence, Tidepool is focusing on real‑world clinical data, especially in resource‑limited care settings. In a 24‑week Diabetes Care Management Program using CGM data streamed through Tidepool’s TIDE clinic dashboard, adults with uncontrolled type 2 diabetes achieved a 1.59% reduction in HbA1c and a 13.4% increase in Time in Range. Tidepool’s remote patient monitoring framework helped clinicians prioritize weekly outreach to patients who most needed support, demonstrating that CGM‑driven workflows can improve outcomes without overwhelming staff. Tidepool is also investing in gender equity through a landmark women’s health initiative, building on menstrual cycle research and partnerships with ŌURA and others. This work aims to create the largest opt‑in dataset connecting diabetes management technology with women’s health, addressing gaps in how continuous glucose monitor data are interpreted for people whose hormones and cycles have often been underrepresented in diabetes research.
How New Evidence Is Changing Clinical Practice for CGM Type 2 Diabetes
Together, the Dexcom CONNECT trial, Tidepool’s real‑world programs, and expanding wearables support are reshaping how clinicians think about continuous glucose monitors in type 2 diabetes. Primary care teams can now point to level A evidence showing that CGM improves HbA1c and time in range even without insulin, while remote dashboards and Apple Watch integrations make it practical to review data between visits. In underserved settings, structured CGM‑based outreach programs show that targeted contact can improve control without exhausting limited resources. As guidelines and payers respond, clinicians may start recommending CGM earlier for patients on oral medications or GLP‑1s who struggle with glucose variability or motivation. Over time, the combination of clinical trials, real‑world evidence and consumer‑grade wearables may shift diabetes management technology from a niche add‑on to a core part of routine care for many people with type 2 diabetes.
